Skip to content

Share Buybacks at other companies

Abbott logo
AbbottABT
$1.05B+17,317%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$460K-23.5%
Medtronic logo
MedtronicMDT
$435M+58.8%
TFX
TeleflexTFX
$0-100%
Haemonetics logo
HaemoneticsHAE
$100M-33.3%
ITG
Integer HoldingsITGR
$50M

Other financials

Income statement

See full
Revenue$1.7B+13.6%
Gross profit$1.3B+13.5%
Operating income$513.2M+24.8%
Net income$241.9M-27.4%
EPS (diluted)$0.42-25.0%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$48.18B+3.7%
Enterprise value$46.44B+11.0%
P/E48×+36.7×
P/S7.4×-0.8×

Profitability

See full
Gross margin77.8%-1.0pp
Operating margin22.3%-3.6pp
Net margin15.4%-57.5pp
FCF margin17.3%

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edwards Lifesciences's share buybacks?
Edwards Lifesciences (EW) reported share buybacks of $421.8M in Q1 2026.
How has Edwards Lifesciences's share buybacks changed year-over-year?
Edwards Lifesciences's share buybacks increased by 63.1% year-over-year, from $258.6M to $421.8M.
What is the long-term trend for Edwards Lifesciences's share buybacks?
Over 4 years (2021 to 2025), Edwards Lifesciences's share buybacks has grown at a 14.9% compound annual growth rate (CAGR), from $512.8M to $893.4M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.